Results 91 to 100 of about 20,748 (167)

VEGFA rs3025039 is associated with phenotype severity of myelofibrosis‐type megakaryocyte dysplasia

eJHaem, 2023
Giovanni Barosi, Paolo Catarsi, Rita Campanelli, Margherita Massa, Adriana Carolei, Carlotta Abbà, Annalisa deSilvestri, Robert Peter Gale, Vittorio Rosti   +8 more
doaj   +1 more source

The Intricate Dance Between Inflammation and Myeloproliferative Neoplasms: From Origins to Outcomes. [PDF]

Curr Hematol Malig Rep
Fleischman AG.
europepmc   +1 more source

Clinical Outcomes of Allogeneic Stem Cell Transplantation in Myelofibrosis - A Single Center Experience. [PDF]

Blood Cell Ther
Joshi N, Kulkarni U, Selvarajan S, Lionel S, Korula A, Na F, Lakshmi KM, Maddali M, Sindhuvi E, Balasubramanian P, Abraham A, Mathews V, George B.   +12 more
europepmc   +1 more source

POIESIS: a phase III study of add-on navtemadlin in JAK inhibitor-naïve myelofibrosis patients with a suboptimal response to ruxolitinib. [PDF]

Future Oncol
Vachhani P, Yacoub A, Rampal R, Bradley T, Harrison C, Jain T, Kuykendall A, Palandri F, Mascarenhas J, Al-Ali H, Passamonti F, Rothbaum W, Verstovsek S, Heidel FH.   +13 more
europepmc   +1 more source

Myelofibrosis [PDF]

Proceedings of the Royal Society of Medicine, 1968
J. S. Malpas, Ronald Bodley Scott
openaire   +1 more source

MPIG6B-related thrombocytopenia and myelofibrosis: A case report. [PDF]

Ann Hematol
Wang X, Xue F, Zhang L, Yang R.
europepmc   +1 more source

Application of IVIM in the assessment of the spleen in patients with myelofibrosis. [PDF]

Front Oncol
Bilski M, Sobas M, Pawluś A, Skarupski M, Zimny A.   +4 more
europepmc   +1 more source

Health Care Utilization Databases obtained from health system inform outcome for ruxolitinib treatment in patients with myelofibrosis. [PDF]

Hemasphere
Mora B, Franchi M, Margotto L, Leoni O, D'ippoliti D, Carloni E, Cozzi I, Santelli E, Gemmi F, Szasz C, Maffioli M, Gurnari C, Attardi E, Cattaneo D, Bortolotti M, Fracchiolla NS, Iurlo A, Corrao G, Della Porta MG, Vannucchi AM, Voso MT, Guglielmelli P, Passamonti F.   +22 more
europepmc   +1 more source

Survival and quality-of-life implications of cytopenia trajectories in ruxolitinib-treated myelofibrosis. [PDF]

Cancer
Palandri F, Caocci G, Abruzzese E, Tiribelli M, Morsia E, Farina M, Benevolo G, Beggiato E, Martino B, Pugliese N, Tieghi A, Crugnola M, Binotto G, Cavazzini F, Iurlo A, Isidori A, Dedola A, Scalzulli E, Duminuco A, Cattaneo D, Lemoli RM, Bosi C, Cilloni D, Bocchia M, Pane F, Sartor C, Heidel FH, Breccia M, Branzanti F, Palumbo GA, Bonifacio M, Elli EM.   +31 more
europepmc   +1 more source

Acute psychosis following initiation of ruxolitinib in post-polycythaemia vera myelofibrosis case report. [PDF]

Ann Hematol
Potter LJ, Shetty S, Ceesay MM.
europepmc   +1 more source